492 related articles for article (PubMed ID: 25931815)
1. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.
Leppert W
Drug Des Devel Ther; 2015; 9():2215-31. PubMed ID: 25931815
[TBL] [Abstract][Full Text] [Related]
2. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction.
Leppert W
Curr Drug Targets; 2014 Jan; 15(1):124-35. PubMed ID: 24020972
[TBL] [Abstract][Full Text] [Related]
3. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.
Leppert W; Zajaczkowska R; Wordliczek J
Expert Opin Pharmacother; 2019 Apr; 20(5):511-522. PubMed ID: 30625013
[TBL] [Abstract][Full Text] [Related]
4. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
[TBL] [Abstract][Full Text] [Related]
5. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities.
Leppert W
Contemp Oncol (Pozn); 2012; 16(2):125-31. PubMed ID: 23788866
[TBL] [Abstract][Full Text] [Related]
6. The role of naloxegol in the management of opioid-induced bowel dysfunction.
Leppert W; Woron J
Therap Adv Gastroenterol; 2016 Sep; 9(5):736-46. PubMed ID: 27582887
[TBL] [Abstract][Full Text] [Related]
7. Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study.
Hesselbarth S; Löwenstein O; Cegla T
Scand J Pain; 2014 Apr; 5(2):75-81. PubMed ID: 29913668
[TBL] [Abstract][Full Text] [Related]
8. The place of oxycodone/naloxone in chronic pain management.
Leppert W
Contemp Oncol (Pozn); 2013; 17(2):128-33. PubMed ID: 23788978
[TBL] [Abstract][Full Text] [Related]
9. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group.
Drewes AM; Munkholm P; Simrén M; Breivik H; Kongsgaard UE; Hatlebakk JG; Agreus L; Friedrichsen M; Christrup LL
Scand J Pain; 2016 Apr; 11():111-122. PubMed ID: 28850449
[TBL] [Abstract][Full Text] [Related]
10. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
Morlion B; Clemens KE; Dunlop W
Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
12. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.
Clemens KE; Mikus G
Expert Opin Pharmacother; 2010 Feb; 11(2):297-310. PubMed ID: 20030568
[TBL] [Abstract][Full Text] [Related]
13. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Holder RM; Rhee D
Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
[TBL] [Abstract][Full Text] [Related]
14. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction.
Poulsen JL; Brock C; Olesen AE; Nilsson M; Drewes AM
Clin Exp Gastroenterol; 2014; 7():345-58. PubMed ID: 25278772
[TBL] [Abstract][Full Text] [Related]
15. Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives.
Mehta V; Alaward S; Kuravinakop S; Nikolic S
Pain Physician; 2014; 17(5):415-24. PubMed ID: 25247899
[TBL] [Abstract][Full Text] [Related]
16. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction.
Grønlund D; Poulsen JL; Krogh K; Brock C; Liao D; Gregersen H; Drewes AM; Olesen AE
Eur J Pharm Sci; 2018 May; 117():187-192. PubMed ID: 29432808
[TBL] [Abstract][Full Text] [Related]
17. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
Leppert W
Adv Ther; 2010 Oct; 27(10):714-30. PubMed ID: 20799006
[TBL] [Abstract][Full Text] [Related]
18. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
[TBL] [Abstract][Full Text] [Related]
19. Opioid-induced bowel dysfunction.
Thomas J
J Pain Symptom Manage; 2008 Jan; 35(1):103-13. PubMed ID: 17981003
[TBL] [Abstract][Full Text] [Related]
20. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
